# Ro

**Telehealth marketplace for online doctor visits and prescription delivery for men’s health**

## Revenue

### $598.00M  
2024

## Valuation

### $7.00B  
2025

## Funding

### $1.00B  
2025

## Growth Rate (y/y)

### 66%  
2025

### Details

**Headquarters**  
New York, United States

**CEO**  
Zachariah Reitano

**Website**  
[ro.co](https://www.ro.co/)

### Milestones

**Founding Year**  
2017

### Overview

#### Revenue

Ro Data Summary | Sacra

## Annualized Revenue & Growth

$598.0M
↑ 66.1%YoY

Source: [Sacra](/content/c/ro/index.html)

**Updated:** Apr 13, 2026

Ro's annualized revenue in 2024 was $598M, showing a rise of 66% YoY from $360M in 2023. This growth was driven primarily by the successful launch of Ro Body, a GLP-1–centered obesity management business.

Previously, Ro's revenue was significantly contributed by the Ro man division, addressing erectile dysfunction and men’s health, accounting for ~60% of total revenue in 2021. However, by the end of 2024, the contribution from sexual health is estimated to be roughly ⅓ of total revenue.

In contrast, GLP-1 obesity management has seen substantial growth, expanding from about 3% of total revenue in 2021 to around 40% by the end of 2024. This category has become the main source of incremental revenue growth. In 2024, GLP-1 sales alone generated approximately $370M, supported by monthly care subscriptions and pharmacy economics.

### Valuation & Funding

**Valuation & Amount Raised**

$7.0B  
↑ $1.2B Total Raised

Source: [Sacra](/content/c/ro/index.html)

**Updated:** Apr 13, 2026

Ro completed its most recent funding round in February 2022, raising $150M, leading to a valuation of $7B, an increase from $5B in March 2021, and bringing total funding to $1.0B.

### Valuation & Funding History

| Date      | Event      | Valuation | Amount    | Price | Status |  |
|-----------|------------|-----------|-----------|-------|--------|--|
| Feb 2022  | Follow On  | $7.0B    | $150.0M  | —     | Closed |  |
| Mar 2021  | Series D   | —         | —         | —     | Closed |  |
| Jul 2020  | Series C   | —         | —         | —     | Closed |  |
| Jul 2020  | Series C   | —         | —         | —     | Closed |  |
| Apr 2019  | Series B   | —         | —         | —     | Closed |  |
| Sep 2018  | Series A   | —         | —         | —     | Closed |  |
| Oct 2017  | Seed       | —         | —         | —     | Closed |  |

## Product

Ro’s journey began in 2017 with a focus on understanding the telehealth adoption process. Initial offerings catered to patients with high-intent conditions requiring discretion and convenience. Ro shifted the dynamics of patient-doctor interactions, allowing patients to begin with an online intake, which is reviewed asynchronously by clinicians, enabling ongoing communication through various mediums.

### GLP-1 and Obesity Management

Ro's operations highlight direct collaborations with Novo Nordisk, allowing for affordable access to GLP-1 medications like Wegovy, positioning Ro effectively in the growing obesity treatment market. Additional offerings include oral GLP-1 medications and various other therapeutic solutions.

### Competition

- **Direct-to-Consumer Telehealth Clinics**: Other telehealth companies like Hims & Hers replicate Ro's business model, starting from high-intent categories and expanding into related services.
- **Platform Telehealth Incumbents**: Large companies serving traditional health systems maintain valuable scales that Ro must contend with.
- **Retail Healthcare**: Retail chains provide bundled services that integrate telehealth into broader consumer platforms.

## Risks

1. **Manufacturer Dependency**: Relationships with pharmaceutical companies like Novo Nordisk could shift unexpectedly, affecting Ro's business model.  
2. **GLP-1 Supply Volatility**: Regulatory changes might impact the availability of weight-loss medications.
3. **Brand Investment Returns**: Elevated spending on marketing without corresponding revenue growth could compress margins.

### News

* January 30, 2026 - Ro secures $75M in Series C funding at a valuation of $1B to disrupt healthcare payments.
* January 28, 2026 - Launches Super Bowl ad campaign to promote GLP-1s aiming to reshape consumer perceptions.  
* January 13, 2026 - Partners with Amgen to enhance GLP-1 access, positioning in a lucrative market.